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ABSTRACT 
The covergence of studies in clinical and basic 
sciences has resulted in the definitive identification 
of many intracellular antigens which are the targets 
of autoantibodies in patients with systemic lupus erythe-
matosus, scleroderma, dermatomyositis/polymyositis, 
Sjogren's syndrome, mixed connective tissue disease, 
and drug induced autoimmunity. Immunofluorescence has 
been widely used for detecting antinuclear antibodies. 
Using tissue sections or cells as antigen substrates, 
many intracellular organelles were targets of recognition 
by autoantibodies, since fluorescence could be detected 
in different structural sizes and shapes and localized 
in different cell compartments. 
An enzyme linked immunosorbent assay to detect 
antinuclear antibodies in the sera of patients with 
SLE has been evaluated and compared to fluorescent anti-
nuclear antibody (FANA) assay. In this study, the nuclei 
were isolated from fresh goat liver and antinuclear 
antibodies were used as reagents to identify nuclear 
antigens. Effect of various parameters like storage 
of nuclei, concentration of nuclei and incubation period 
was investigated on assay procedure. It was observed 
that isolated nuclei stored at -20°C can be used for 
ELISA for no longer than one month without appreciable 
loss in activity. The antibody activity was found to 
be dependent upon the number of nuclei coated on the 
polystyrene surface and maximum antibody activity 
occurred with the antigen concentration of 1000 nuclei/ 
50pL. SLE sera tested by this procedure indicated high 
titre of antinuclear antibody activity. 
Prototype sera (reference sera) with known anti-
body specificities were used as an important feature 
in this study. The prototype sera with antibody specifi-
city to nuclear antigens like nDNA, RNP, Sm, nucleolus. 
II 
centromere, ANA (UIRNP, SSB/La, SSA/RO and Scl-70 demons-
trated strong antibody activity against purified nuclei 
by ELISA. The method is highly sensitive employing 1:1000 
diluted serum and the results thus obtained are reprodu-
cible on the basis of data for intra -and interassay 
coefficient of variations. 
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I INTRODUCTION 
The function of the immune system is to discrimi-
nate between self and non-self and mount responses to 
rid the body of potentially life threatening non-self, 
for example, viruses. However, this enormous recognition 
potential includes possible interactions with self compo-
nents, some of which appear to be essential for the 
regulation of immune functions (Jerne, 1974), whereas 
others can be pathogenic particularly if expressed at 
high levels. Pathogenic expression of self reactivity 
may result from abnormalities in the generation of the 
T and B cell receptor repertoire. 
A normal immune response is initiated by antigen 
presenting cells (Seeger, et al. 1970; Stingl et al. 1980; 
Chesnut, et al. 1981), presenting the foreign antigens 
in combination with the MHC II gene product to helper 
cells which very effectively cooperate with B-lymphocytes 
bearing the same MHC II gene product complexed with 
the antigens bound by surface IgG receptors. These helper 
T-cells also support other T-lymphocytes, for example, 
cytotoxic T-cells recognizing foreign antigens complexed 
with MHC I gene product on different cells (Bicker,1986). 
During the T-B cell contact the B-cells become 
vulnerable to a B-cell growth factor produced by the 
antigen-specifically activated, T-helper cells (Martinez, 
et al. 1981). 
Autoimmunity and Autoimmune Disease 
Two commonly accepted opinions regarding the 
response of immune system against self-components and 
especially against key points in the regulatory system 
have been put forward (Roitt, 1984). Either (i) an age-
dependent breakdown of self tolerance occurs i.e. there 
is less stringent supression of self reactive lymphocytes> 
or (ii) seif-reactive antibodies have a true biological 
function, acting as transporting agents for cellular break-
down products, thereby aiding their disposal. A third 
possibility explains the age-dependent increase in auto-
antibodies, their association with certain MHC antigens 
and the development of the potentially dangerous specifi-
cities against receptors or their ligands (Blecher, 1984). 
Receptors and their ligands constitute the basis for ade-
quate function of multicellular organism. Disturbance 
of the normal signal by stimulation of the receptor with 
inadequate ligands may lead to disease, for example, cancer 
(Berridge, 1985). 
Of various autoimmune disease, systemic lupus 
erythematosus (SLE) is a prototype autoimmune disease 
characterized by an increased immunoglobulin level and 
autoantibody production. Immunoglobulins may combine 
with exogenous antigens or autoantigens, resulting in 
immune complexes which damage endothelial cells and other 
tissues by a cascade of events involving complement, leuko-
cytes, platelets and vasoactive substances (Theofilopoulos, 
1982). The most characteristic of autoantibodies are anti-
bodies to components of the cell nucleus or antinuclear 
antibodies (ANA) (Reichlin, 1981; Tan, 1982), routinely 
detected by the fluorescent antinuclear antibody (FANA) 
assay. With this assay, ANAs can almost be invariably 
demonstrated in the sera of patients with SLE, although 
heterogeneity in the appearance of FANAs suggest recogni-
tion of various target antigens. 
Using tissue sections or cells as antigen substrates 
in immunofluorescence, it was apprecicted that many intra-
cellular organelles were targets of recognition by auto-
antibodies, since fluorescence could be detected in diff-
erent structural sizes and shapes and localized in diff-
erent cell compartments. These observations provided the 
initial data that multiple antibodies; occured in certain 
diseases and that various intracellular molecules might 
be antigenic (Tan, et al. 1988). So called FANA negative 
SLE patients may express antibodies to nuclear antigens 
or related material that are not well represented or acce-
ssible in conventional FANA substrates (Maddison, et al. 
1981 ). 
Immunodiffusion analysis was an important tool 
for detecting precipitating antibodies to soluble intra-
cellular antigens. Combination of biochemical separation 
techniques with immunodiffusion analysis resulted in the 
partial characterization of a soluble non-histone nuclear 
protein designated the Sm-antigen and this system of analy-
sis has been used for the subsequent immunological identi-
fication of many other nuclear and cytoplasmic antigens. 
The Farr ammonium sulphate technique and Milli-
pore filterassay are sensitive methods for measuring auto-
antibodies. Both are radioimmunoassays which require the 
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use of H and C lebelled DNA. Radioactive nDNA can be 
prepared from viral, bacterial and human cell line in 
culture (Hillyer, et al. 1980), but the methods of isola-
tion and purification are technically complex and feasible 
for specialized laboratories. The effect of non-specific 
binding caused by the interaction between gamma ( Y ) globu-
lin and denatured DNA was markedly reduced by the addition 
of dextran sulfate or calcium chloride at allcaline pH 
(Akira, et al. 1979) . 
Autoantibodies have been instrumental in elucida-
ting the mechanism of splicing of precursor mRNA (Brunei, 
et al. 1985; Bozzoni, et al. 1984; Fradin, et al. 1984), 
in the discovery of new species of small nuclear RNAs 
(Lerner, et al. 1979; Reddy, et al. 1983a, Reddy, et al. 
1985), in characterizing the nature of protein binding 
to nascent RNA polymerase III transcripts (Lerner, et 
al. 1981a;, Hendrick, et al. 1981; Rinke, et al. 1982; 
Reddy, et al. 1983b), in mechanisms related to cell 
division (Miyachi, et al. 1978; Takasaki, et al. 1981; 
Mathews, et al. 1984a; Moroi, et al. 1980; Earnshaw, 
et al. 1985), and in cloning of genes encoding proteins 
involved in important cell functions (Chambers, et al. 
1985; Wieban, et al. 1985; Theissen, et al. 1986; Habets, 
et al. 1987; Earnshaw, et al. 1987; Matsumoto, et al. 
1987). 
With progressive characterization of the immuno-
chemical and molecular nature of autoantigens, it has 
become increasingly clear that autoimmune diseases are 
distinguished by different sets of autoantibodies which 
tend to stamp each disease with its own individual profile. 
The majority of these autoantibodies are targeted at 
nuclear (nucleoplasmic and nuclear matrix) antigens but 
there are others reactive with nucleolar and cytoplasmic 
antigens (Tan, et al. 1988). 
Antinuclear Antibodies 
Antinuclear antibodies are humoral antibodies 
that occur spontaneously in the blood of the patients 
with systemic lupus erythematosus, progressive systemic 
sclerosis (PSS or scleroderma) rheumatoid arthritis (RA) 
and Sjogren's syndrome (SS) (Tan, 1984). There are several 
features of antinuclear antibodies and their relationship 
to disease which stand out. Some ANAs include anti native 
DNA (Stollar, 1986) and anti-Sm (Conner, et al. 1982; 
Fisher, et al. 1983) in SLE, anti-Scl-70 (Jarzabek-Chorze-
Iska, et al. 1986 in diffuse scleroderma, anti-centromere 
(Earnshaw, et al. 1985) in CREST (calcinosis, Raynaud's 
esophageal dysmotility, schlerodactyly, and telangiectasia) 
and anti-tRNA synthetases (Yang, et al. 1984; Mathews, 
et al. 1984b; Bunn, et al. 1986; Okada, et al. 1987) 
in dermato/polymyositis. Other ANAs are found in several 
diseases but differ markedly in prevalence. Such ANAs 
include antihistones (Rubin, et al. 1982; Rubin, et al. 
1985; Portanova,et al. 1987) in SLE and drug induced lupus, 
anti U1RNP (Conner, et al. 1982; Fisher, et al. 1983) 
in SLE and mixed connective tissue disease (MCTD) and 
anti-SSA/Ro (Yamagata, et al. 1984; Harmon, et al. 1984) 
and anti-SSB/La (Lerner, et al. 1981a; Reddy, et al. 1983b; 
Chan, et al. 1986; Chan.et al. 1987) in SLE and Sjogren's 
syndrome. Some of the current information on ANAs is 
presented in Table 1. 
IgG Subclasses of ANA 
Awareness of different biological properties 
of the four-human IgG subclasses has stimulated efforts 
to determine to which subclasses autoantibodies belong. 
Of particular interest is the complement activating poten-
tial of IgGi and IgG3 and the capacity of these subclasses 
to bind Fc receptors on mononuclear cells (Spiegelberg, 
1974). Before the availability of monclonal antibodies 
specific for each subclass, only a general and in part 
inconsistent, picture of autoantibody subclasses of anti-
DNA (Tojo, et al. 1970) and antinuclear antibodies (Kacaki, 
et al. 1971) were present at titres that reflected the 
serum levels of these immunoglobulins. Zouali, et al. 
(1984) showed the most dramatic s)<ewing of anti-native 
DNA to the IgGi and IgG3 subclasses and found anti-ribonu-
cleoprotein (RNP) to be predominately IgG2. In contrast 
a major restriction to IgGi was observed by Eisenberg, 
et al. (1985) for anti-RNP and anti-Sm and by Pearce, 
et al. (1966) for anti SSB/La. 
Autoantibodies to DNA 
Antibodies to DNA can be divided into three 
major groups on the basis of specificity : 
1. Anti-native DNA antibodies: Antigenic determinant related 
to doublehelical structure of DNA (Arana, et al. 1967; 
Stollar, 1986). 
2. Anti-native DNA antibodies reacting in identity with 
anti-single stranded DNA : anhigenic determinant 
related to deoxyribose-purine-pyrimidines, but not 
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dependent on double helix or on purines and pyrimidines 
alone (Arana, at al. 1967; Tan, et al. 1966; Stollar, 
1973). 
3. Anti-single stranded DNA antibodies : Antigenic deter-
minant related to purines and pyrimidines. Also reac-
tive with purines and pyrimidines in RNA (Arana, et 
al. 1971; Stollar, et al. 1962; Tan, 1967; Rubin, 
et al. 1986a). 
Antibodies to DNA react with many different determi-
nants in the DNA molecule. There have been a few sera 
described that appear to react with the double helical 
structure of native DNA and do not cross react with single 
stranded DNA. However, the majority of antinuclear antibo-
dies that react with native DNA cross react in immunologic 
identity with single stranded DNA, suggesting that the 
reactive determinant in DNA is probably composed of the 
deoxyribose-phosphate backbone either with or without 
the association of purines and pyrimidines (Stollar, 1973). 
Double stranded DNA may contain single stranded regions 
from breaks of gaps in the molecules; there may also be 
some breathing of structure with ssDNA regions occassio-
nally revealed. Similarly, ssDNA preparations may have 
regions of dsDNA possibly from intramolecular hydrogen 
binding and local duplex formation. These considerations 
suggest that the distinction between anti-double stranded 
and anti-single stranded DNA is operational although valua-
ble because of the diagnostic utility of anti-dsDNA deter-
mination (Barnett, 1979; Stollar, et al. 1980). Other 
subpopulations of anti-DNA antibodies may also occur. 
They may recognize the backbone of one strand and may 
be able to react with both native and denatured DNA. 
Most of the current anti-double stranded DNA 
assays employ double stranded DNA preparations in which 
contamination by ssDNA is minimized. These antigens can 
be obtained by digestion of dsDNA by nucleases specific 
for ssDNA or from microorganisms that have closed circular 
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dsDNA (Aarden, et al. 1975a). Detection systems include 
immunodiffusion, hemagglutination; Farr binding; filter 
binding; crithidia immunoflurescence; and solid-phase 
enzyme linked immunosorbent assay (ELISA). These assays 
provide quantitative information that differs markedly 
in content. Thus, Farr and filter binding assay are repor-
ted in terms of the quantity of antigen that is bound. 
Crithidia assay provide a titre while ELISA assays provide 
a titre or color yield at a given serum dilution (Wold, 
et al. 1968; Kredich, et al. 1973; Aarden, et al. 1975b; 
Pisetsky, et al. 1981; Ali, et al. 1983; Ali and Ali, 
1983a; Ali and Ali, 1984; Ali and Ali, 1983b; Ali and 
Ali, et al. 1985a; Kumar and Ali, 1984). A direct role 
of anti-DNA in the immunopathology of SLE has been estab-
lished (Koffler, et al. 1971). Anti-DNA has been eluted 
from kidneys of patients with SLE, presumably deposited 
as immune complexes. Anti-DNA has been demonstrated in 
circulating immune complexes or cryoprecipitates, although 
this finding has been variable. 
The advent of monoclonal auto-antibodies has 
provided new systems for elucidating the expression of 
anti-DNA antibodies and their pathogenetic role (Eilat, 
1982; Andrezejewski, et al. 1980; Hahn, et al. 1980; 
Tron, et al. 1980; Lerner, et al. 1981b, Pisetsky, et 
al. 1982; Lafer, et al. 1981; Ali, et al. 1985b). 
The prototype anti-DNA monoclonal antibodies 
have demonstrated several distinct patterns of idiotypic 
expression, including both private and public specifici-
ties (Pisetsky, 1983; Rauch, et al. 1982; Datta, et al. 
1983; Marion, et al. 1982; Teitelbaum, et al. 1984; Hahn, 
et al. 1984). 
Autoantibodies to Nucleoprotein 
Antibody to nucleoprotein, or the DNA-histone 
complex, is of biological as well as historical significance, 
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This particular ANA is in fact the antinuclear antibody 
responsible for the LE cell phenomenon, and is thus the 
well known LE factor in the serum of patients with SLE. 
It has been shown by a number of studies that antibodies 
of this specificity will react only with the complex 
of DNA and histones and that if this comples is dissocia-
ted by enzyme treatment, the separate moities of either 
DNA or histones are no longer reactive with the antibody 
(Tan, 1967). 
Autoantibodies to Histones 
Antibodies to histones which are basic nuclear 
proteins occur mainly in drug-induced autoimmunity, in 
SLE, and in a small proportion of patients with rheumatoid 
arthritis (Rubin, 1987). Most patients treated with proca-
inamide to control cardiac arrhythmas eventually develop 
antihistone antibodies, but symptomatic disease occurs 
in only 10-20% of procainamide-treated patients (Woosley, 
et al. 1987). Thus the majority of antihistone antibodies 
are apparently benign, and examination of their class 
and fine specificity revealed that anti-histone antibodies 
in asymptomatic patients are predominantly IgM and display 
broad reactivity, with all the individual histones. In 
contrast, patients with symptomatic procainamide-induced 
lupus have a unique type of IgG anti-histone antibody 
which, rather than reacting with individual histones, 
displays pronounced reactivity with the histone (H2A-H2B) 
dimer (Rubin, et al. 1985; Rubin, et al. 1986b). 
Autoantibodies to Non-Histone (Acidic) Nuclear protein 
Antibodies to nuclear non-histone protein Sm, 
with the Sm designation derived from a patient's name, 
provide a serological marker of SLE (Lerner, et al. 1979; 
Conner, et al. 1982; Fisher, et al. 1983). Like anti-DNA, 
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anti-Sm can function as a diagnostic marker, although 
the pattern of expression and postulated disease role 
differ from anti-DNA (Notman, et al. 1975^. Thus anti-
Sm levels frequently do not parallel disease activity 
and are relatively uncharged by exacerbations or treatment. 
In the same patients with stable anti-Sm, anti-DNA may 
show fluctuations in accord with activity, suggesting 
independent expression (McCarty, et al. 1982). 
Anti-Sm also has not well correlated with patterns 
of disease involvement especially nephritis, and a consis-
tent role in immune complex formation has not been demons-
trated. The biochemical structure of Sm has recently 
been elucidated using anti-Sm as a probe. Sm has been 
shown to a ribonucleoprotein complex comprised a unique 
set of small RNA, U. , U_, U., U^ and U, and protein mole-
cules (Lerner, et al. 1979; Lerner, et al 1981c). This 
structure termed snRNP for small nuclear ribonucleoprotein, 
is highly conserved among species, possibly because of 
a critical role in cellular RNA metabolism (Sharp, 1987; 
Rogers, et al. 1980; Yang, et al. 1981). 
It is generally accepted that there are two kinds 
of complexes, RNP-Sm complexes, which have the RNP and 
Sm antigenic reactivities and Sm-complexes, which have 
Sm antigenic reactivity only (Buchanan, et al. 1983; 
Kinlaw, et al. 1983; Ishaq and Ali, 1983a). Anti-Sm anti-
bodies recognize some of the 'Core' proteins usually 
proteins B,B' and D, which seem to be present in all 
complexes. Anti-Sm antibodies are also present in MRL/MPJ-
Ipr/lpr mice a murine model of SLE (Eisenberg, et al. 
1978;' Eisenberg, et al. 1982; Pisetsky, et al. 1980^. 
Monoclonal anti-Sm antibodies from MRL/MPJ-lpr/lpr mice 
have been used to prepare antiidiotypic reagents. 
In MRL mice, the antibody is mostly of IgG2a 
subclass. Although this is a T-dependent isotype (Mongini, 
et al. 1981), it is not the usual dominant antibody 
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species in immune responses to exogenous T-dependent 
antigens (Slach, et al. 1982). In humans, the anti-Sm 
response is highly restricted to the IgGI subclass, which 
is also T-dependent. In spite of this isotype restriction, 
the human anti-Sm response appears to be polyclonal 
because kappa and lamda light chain anti-Sm antibodies 
are expressed in the expected 60:40 ratio and because 
isoelectic focussing patterns show no apparent restriction. 
Another solub.le antigen closely related to Sm 
is RNP. RNP is a component, along with Sm, of ENA (extra-
ctable nuclear antigen) but distinguishable from Sm beca-
use of sensitivity to ribonuclease digestion (Kumar and 
Ali, 1986; Ishaq and Ali, 1987). Anti-RNP was originally 
postulated as a marker for an entity called mixed connec-
tive tissue disease (MCTD). In addition, anti-RNP can 
be seen in patients with SLE without clinical features 
of MCTD. Indeed, in patients with SLE, there is a close 
association between anti-RNP and anti-Sm expression, 
with most anti-RNP positive patients also positive for 
anti-Sm. The relationship between RNP and Sm extends 
to the structural level. The RNP antigen is also a snRNP, 
although it contains only species of RNA called U1 in 
addition to the protein components. Anti-RNP antibodies 
recognize three proteins, a 68kd protein, and proteins 
A (33kd) and C (22kd) (Kinlaw, et al. 1983; Petterson, 
et al. 1984; Mimori, et al. 1984; Habets, et al. 1985; 
Ishaq and Ali, 1983b). Nevertheless it has been shown 
that anti-RNP antibodies have some reactivity (detected 
by blotting) with the "Core" proteins B and B', despite 
the fact that not all complexes with these proteins are 
precipitab]e by anti-RNP sera (Petterson, et al. 1984; 
Habets, et al. 1985). As in the case of anti-Sm a patho-
genetic role for anti-RNP has not been well established 
(Lerner, et al. 1979; Lerner, et al. 1981b; White, et 
al. 1981; Sharp, et al. 1972; Mattioli, et al. 1973). 
Antibodies against these highly conserved molecules have 
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been induced in experimental animals (Ishaq and Ali 1984; 
1986). Patients with MCTD react with another nuclear anti-
gen hnRNP/RNA of nuclear matrix (Fritzler, et al. 1984). 
Autoantibodies to SSA/RO and SSB/La 
Antibodies to soluble cellular protein antigens 
SSA/RO and SSB/La are most commonly found in patients 
with Sjogren's syndrome. These autoantibodies are also 
present in SLE but in somewhat lower prevalence with 
anti-SSA/Ro in 60% of Sjogren's syndrome and 35% of SLE 
and anti-SSB/La in 40 and 15% respectively. In fact it 
was this situation which led to their detection in 
Sjogren's syndrome by one group of ivestigators (Alspaugh, 
et al. 1976) and in SLE by another {Mattioli, et al. 1974). 
The SSA/RO antigen has been shown by immunoprecipi-
tation and western blotting to be a protein of approxima-
tely 60 k6 complexed with several small RNAs which are 
thought to be cytoplasmic and called Y. and Y RNAs 
(Y derived from cytoplasm). Antibodies to SSA/RO are pre-
sent in high prevalence in a clinical entity whichis regarded 
as a subset of SLE called subacute cutaneous lupus (Tosokos, 
et al. 1987). The antigen appears to be present in low 
abundance in certain animal species and because of this, 
patients with anti-SSA/Ro antibodies may appear to be 
negative for ANAs especially if tissues from these animal 
species are used as substrates in immunofluorescence 
(Harmon, et al. 1984). When the appropriate substrates 
are used, such as human tissue culture cells, the majority 
of these sera show finely punctate pattern of nuclear 
fluorescence. 
A feature of SSA/RO antibody which is of increasing 
clinical interest in its association with complete congeni-
tal heart block in infants born of mothers who carry this 
antibody (Franco, et al. 1981). It has been shown that 
the antibody in the infants is maternally transferred 
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(Scott, et al. 1983) and follow-up studies show that there 
is increased risk of the baby having skin rash and congeni-
tal heart block (Ramsy-Goldman, et al. 1986). 
The SSB/La antigen is a nucleoplasmic protein of 
48 kd and has the interesting property of complexing with 
transcripts of RNA polymerase III as soon as the RNA trans-
cripts are synthesized. These include precursor transfer 
RNAs, 5S RNA and 7S RNA. Antibody to the protein has been 
detected in approximately 40% of patients with Sjogren's 
syndrome and it appears that the only other disease where 
the antibody has been detected in SLE (15%). 
Like Sm and U1 RNP, the SSB/La and SSA/RO antigens 
are detectable in the form of ribonucleoprotein particles. 
Much like the association of Sm and U1 RNP particles, 
the SSA/RO and SSB/La particles appear to have affinity 
for each other. The parallel with Sm and U1 RNP extends 
even further in that patients with anti-SSB/La frequently 
have concomitant anti-SSA/Ro just as the patients with 
Anti-Sm frequently have antobody to Ul RNP. However, there 
are some patients who have antibody to SSA/RO alone without 
anti-SSB/La, reminiscent of patients with MCTD who have 
anti-UlRNP without anti-Sm. 
A distinctive group of antibodies directed aganist 
transfer RNA (tRNA) synthetases occur in autoimmune myosi-
tis. Antibody to histidyl tRNA synthetase occurs in highest 
prevalence in polymyositis (about 25%) and appears to be 
identified with a subset of patients who have associated 
intersititial lung disease (Bernstein, et al. 1984). Anti-
bodies to threonyl and alanyl tRNA synthetases occur 
in lower prevalence. Human autoantibodies have the ability 
to interfere with function by inhibiting the catalytic 
activity which charges the tRNA with the relevant amino 
acids (Mathews, et al. 1983; Mathews, et al. 1984b; Bunn, 
et al. 1986). The antigenic determinants recognized by 
autoantibodies reside on the transferase proteins 
16 
themselves so that if the antigen preparations were depro-
teinized, tRNAs were not precipitated. Exception being 
the alanyl tRNA (Bunn, et al. 1986). 
Anti-PM-Scl (polymyositis-scleroderma overlap^ 
is an antibody recognized by immunofluorescence as staining 
of nucleolus and cytoplasm (Reichlin, et al. 1984) and 
by immunoprecipitation of a complex of 11 polypeptides 
ranging from 110 to 120 kd (Reimer, et al. 1986). Patients 
with these antibodies have a clinical syndrome showing 
overlapping features of polymyositis and scleroderma. 
Other autoantibodies in dermato/polmyositis recog-
nize an initiator methionine tRNA ,a 54 kd protein of the 
signal recognition particle and an unindentifled antigen 
present in calf thymus extracts called Mi-2 (Targoff, 
et al. 1985b; Wilusz, et al.1986; Reeves, et al. 1986; 
Okada, et al. 1987). 
Autoantibodies to Scl-70 
Autoantibodies to an entirely different set of 
cellular antigens are observed in scleroderma. A major auto-
antigen is Scl-70 which is a 70 kd protein and has been 
shown to be a degradation product of DNA topoisomerase 
I. The antibody was originally detected by immunodiffusion 
and the initial immunofluorescence data led to the conclu-
sion that the antigen was localized in a punctate distri-
bution in the nucleoplasm. The antibody appears to be 
a good marker for the diffuse form of scleroderma (Jarzabek-
Chorzelska, et al. 1986) in contrast to antibody to centro-
mere/kinetochore antigens which show high selectivity 
for the CREST subset of scleroderma (Moroi, et al. 1980; 
Earnshaw, et al. 1985). The antigenic targets of CREST 
autantibodies are in the centromeric regions of chromosomes 
and are proteins of 17,80 and 140 kd tightly bound to 
centromeric chromatin (Earnshaw, et al. 1985). 
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Autoantibodies to Nucleolus 
Antinucieolar antibodies were recognized more than 
10 years by immunofluorescent studies. However, it has 
only recently been possible to characterize the nuclear 
macromolecules that react with antibodies of this type. 
These include RNA polymerase I which is immunoprecipitated 
from nucleolar extracts as a complex of subunit proteins 
ranging from 210 to 211 kd. Microinjection of IgG autoanti-
body into the frog oocyte effectively inhibited synthesis 
of 28 and 18S ribosomal RNA (Reimer, et al. 1987a). A 
second nucleolar antigen is PM-Scl. The third nucleolar 
antigen is fibrillarin, a 34 kd protein rich in dimethyl 
arginine and glycine (Lischwe, et al. 1985) and recently 
shown to be a component of the U^ RNP particle (Reimer, 
et al. 1987b). There are other autoantibodies which have 
been detected infrequently and the antigenic targets are 
7-2 and 8-2 RNAs, a 68kd protein complexed v/ith Alu RNA 
nuclear lamin proteins (Mckeon, et al. 1983). 
There are other antinuclear antibodies that react 
with fibrous or particulate nucleoproteins. The precise 
specificities of the latter group of antibodies have not 
been characterized. Fibrous or particulate nucleoprotein 
might reasonably be expected to contain atleast a number 
of different nuclear macromolecules which might possess 
antigenic determinants reacting with anti-nuclear antibo-
dies. (Beck, 1961; Lachmann, et al. 1961). 
In additon to antibodies to nuclear components, 
there is production in autoimmune disease (SLE) of auto-
antibodies to other macromolecules, such as cell surface 
antigen structures on red cells, platelets and T-cells 
(Pisetsky, 1984). 
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Objectives of the Present Study 
An enzyme linked immunosorbent assay was evaluated 
as an alternative to fluorescent antinuclear antibody 
(FANA) assay for the evaluation of ANA. Purified nuclei 
from goat liver were used as the antigen source to detect 
antinuclear antibodies in patients with SLE. Effect of 
various parameters like concentration of nuclei, storage 
of nuclei below 0 C and incubation period was investigated 
on the assay procedure. 
Sera from patients with SLE in addition to the sera 
containing antinuclear antibodies, prototype sera (refer-
ence sera) with known antibody specificities were also 
used in this study. Prototype sera with antibody specifi-
city to nuclear antigens nDNA, non histone (acidic) 
nuclear antigens RNP and Sm, nucleolus, SSA/RO, SSB/La, 
centromere and Scl-70 were also evaluated by this assay. 
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II EXPERIMENTAL 
A. MATERIALS 
1. Chemicals 
Bovine serum albumin (BSA) and antihuman IgG alka-
line phosphatase conjugate were purchased from Sigma 
Chemical Company, U.S.A. p-Nitrophenyl phosphate was 
obtained from C.S.I.R. Centre for Biochemicals, Delhi. 
Polystyrene flat bottom plates having 96 wells (7 mm 
in diameter) were obtained from Dynatech, U.S.A. Tween-20 
was purchased from Bio-Rad laboratories, U.S.A. Sodium 
azide was obtained from Ferak-Berlin, West Germany and 
sucrose from Glaxo, India. Phenylmethyl-sulfonyl fluoride, 
polyvinyl sulphate, spermine and spermidine were from 
Sigma Chemical Company, U.S.A. Ethylene glycol bis (3-
aminoethyl ether) N,N,N',N'-tetra acetic acid (EGTA) 
was purchased from Koch-Light laboratories, England. 
Nonidet p40 was from BDH Chemicals England, Ficoll-400 
was obtained from pharmacia Fine Chemicals, Sweden. All 
other chemicals used were of highest grade available. 
2. Equipment 
Shimadzu UV240 spectrophotometer, Dynatech ELISA 
microplate reader MR 600, ELICO pH meter model L1-10T, 
Bausch and Lomb Spectronic 20 were the major equipment 
used in this study. 
3. Sera Specimens 
Normal human sera were obtained from healthy subj-
ects. Sera of patients with systemic lupus erythematosus 
and other autoimmune diseases were obtained from outdoor 
and indoor patients of the Department of Medicine, All 
India Institute of Medical Sciences, New Delhi and J.N. 
Medical College, A.M.U., Aligarh. The samples were 
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transported to the laboratory on ice sodium chloride 
mixture. Patients with these diseases had features meeting 
preliminary criteria of the American Rheumatism Associa-
tion for these diseases (Tan, et al. 1982). All sera 
were stored at -20 C with 0.1 percent sodium azide as 
preservative until examined. Serum samples were decomple-
o 
mented before use by heating at 56 C for thirty minutes. 
Reference sera were obtained from centre for 
Disease Control atlanta, Georgia, U.S.A. The sera were 
rehydrated with 0.5 ml distilled water before use. 
4. Organ 
Liver was obtained promptly after the slaughter 
of the animals and immediately frozen in ice-sodium chlo-
ride mixture and transported to the laboratory. 
B. METHODS 
1. Preparation of Antigen 
Nuclei were isolated essentially according to 
the procedure described by Douvas et al. (1979b) with 
some modifications. All procedures were carried out at 
4°C. Acid washed glassware and sterilized solutions were 
used throughout all operations to prevent nuclease and 
protease activity. 
a. Homogenizing medium 
Homogenizing medium (HM) contained 250mM sucrose, 
5mM magnesium acetate, 0.1mM EGTA and 5mM 2-mercapto-
ethanol. In addition, it contained ImM phenylmethyl-sulfo-
nyl fluoride (PMSF), ImM spermine, ImM spermidine and 
lOpg/ml polyvinyl sulfate. PMSF was dissolved in minimal 
volume of isopropyl alcohol and then added to homogenizing 
medium immediately before use. 
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b. Homogenizing medium with nonidet P-40 (HM-40) 
HM-40 contained all the above components plus 
0.5 percent (v/v) nonidet P-40. 
c. Procedure 
Frozen liver was thawed in homogenizing medium 
for 20-30 minutes. The thawed tissue was cut into small 
pieces and homogenized with chilled HM for short period 
to avoid nuclear disintegration. The homogenate was 
filtered through 3-4 layers of cheese cloth. The filtrate 
was centrifuged at 2,500-3000 rpm (600-800g) for 10 
minutes. The pellet was washed twice and suspended in 
HM-40 and carefully stirred for 30 minutes. The suspen-
sion was centrifuged and the pellet washed thrice with 
HM-40. The final washing of the pellet was performed 
with homogenizing medium. 
2. Purification of nuclei 
a) Reagents 
0.25 M sucrose - 0.003 M CaCl2 
Stock Ficoll solution 
100 g of Ficoll was dissolved in 100 ml of 0.25M sucrose-
0.003M calcium chloride. 
b) Procedure 
The isolated nuclei were suspended in 0.25M 
sucrose-0.003M CaCl^ (8 ml) and carefully layered over 
3 ml of stock Ficoll solution in a graduated centrifuge 
tube. The layered suspension was centrifuged at 700g 
for ten minutes and the purified nuclei were collected 
at the bottom of the centrifuge tube. The purified nuclei 
were observed under light microscope using hematoxylene 
stain. 
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3. Staining of Nuclei 
a. Adhesive solution 
Glycerin - egg albumin mixture was used to fix 
the cells on slides. 
Egg Albumin 1 part 
Glycerin 1 part 
The solution was mixed well with a mechanical 
mixer and filtered. 
b. Hematoxylin 
Ehrlich's hematoxylin. 
Hematoxylin 0.67 g 
Absolute alcohol 33 ml 
Distilled water 33 ml 
Glacial acetic acid 3.3 ml 
Hematoxylin was dissolved in alcohol and other 
constituents were then added. 
c. Procedure 
The nuclei were stained in hematoxylin Ehrlich's 
mixture for 10-15 minutes. The slides were washed with 
tap water to remove the excess stain. The smears were 
dehydrated (for a few seconds) in one percent hydrochloric 
acid in 70 percent alcohol. The slides were washed for 
5 minutes in running tap water and placed in 70 percent 
alcohol for 2-3 minutes. These were then transferred 
directly to 95 percent alcohol and left for half a minute. 
Slides were transferred to absolute alcohol and finally 
were left in xylene for 2-3 minutes. A small drop of 
mounting solution (glycerin) was placed onto the slide 
and covered with cover slip. The nuclei were stained 
deep blue. 
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3. Enzyme Linked-Immunosorbent Assay (ELISA) 
a. Buffers and Reagents 
Bicarbonate buffer I - 15 mM carbonate, 35 mM 
sodium bicarbonate pH 9.6 containing 0.02 percent azide 
as preservative. 
Saline-Tween 20 - 0.15 M sodium chloride and 0.05 per-, 
cent Tween-20, pH 7.2. 
Bicarbonate buffer II - 0.05 M sodium bicarbonate/Carbo-
nate pH 9.5 containing 2 mM magnesium chloride. 
Substrate - 500 pg p-nitrophenyl phosphate in 1 ml of 
bicarbonate buffer II. 
b. Procedure 
Antibodies in SLE and immune serum were detected 
and quantitated by ELISA as described earlier (Ali, et 
al. 1985a). All steps were carried out at room temperature 
unless mentioned otherwise. 
Polystyrene microtitre plate was incubated with 
50 uL nuclear suspension (1000 nuclei/50)aL) in carbonate/ 
bicarbonate buffer, pH 9.6) for two hours and overnight 
at 4°C. The plate was washed three times with saline-
Tween 20(ST-20) and unoccupied sites were blocked with 
one percent BSA in ST-20 for 6 hours. Decomplemented 
sera (dilutions in ST-20) was adsorbed for two hours 
and overnight at 4 C. The unbound material was washed 
four times with ST-20 and appropriate anti-human IgG 
alkaline phosphatase conjugate (1:1500 dilution in ST-20) 
was added. After two hours, the plate was washed four 
times with ST-20 and two times with distilled water. 
Substrate (PNP-P, 5x10" M in bicarbonate buffer containing 
3mM magnesium chloride, pH 9.5) was added and absorbance 
recorded at 410 nm with ELISA micro reader after proper 
color development. In each step 100 uL of solutions were 
added and each sample was run in duplicate. The control 
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wells were treated similarly but were devoid of antigen. 
4. Intra-and interassay coefficient of variation 
The intra-and interassay variability of ELISA 
was determined by testing five SLE sera and two normal 
human sera. For intraassay variation the samples were 
tested eight times in a day. Interassay variation was 
determined by testing the same serum samples for eight 
consecutive days. In both assays a single dilution of 
sera was studied. 
5. Anti-DNA antibody Assay 
(a) Buffers and Reagents 
Tris buffer Saline (TBS)-IOmM Tris, 150 mM 
sodium chloride, pH 7.4. 
TBS-T pH 7.4 - Tris (2.4g), sodium chloride (8.0g), 
potassium chloride (0.2g), Tween-20 (0.05%) in 
1 litre solution. 
Bicarbonate buffer - 0.05 M sodium bicarbonate-carbo-
nate pH 9.5 containing 2mM magnesium chloride. 
Substrate - p-Nitrophenylphosphate (500 pg) per ml in 
bicarbonate buffer. 
b. Procedure 
Technique of Zouali and Stellar (1986) with slight 
modification was used for the detection and quantitation 
of anti-DNA antibodies in SLE and immune serum. All steps 
were carried out at room temperature unless mentioned 
otherwise. Polystyrene microtitre plate was incubated 
with 100 uL poly-D-lysine (50 >ig/ml in distilled water) 
for 30 minutes. The plate was washed three times with 
TBS. DNA (2.5 pg/ml TBS) was coated for 2 hrs. and over-
night at 4 C. The uncoated antigen was washed three times 
with TBS. The remaining positive charge was neutralized 
by adsorption with poly-L-glutamate (50 pg/ml in TBS) 
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for 2 hrs. Unoccupied sites were blocked with 1% BSA 
in TBS (TBS-BSA) for 4 hrs. Decomplemented sera (dilutions 
in TBS-BSA) were adsorbed for 2 hrs. and overnight at 
4°C. After washing four times with TBS-T anti-IgG-alkaline 
phosphate conjugate (1:1500 dilution in TBS-T) was added, 
Sbustrate was added after four washing with TBS-T and 
the absorbance was recorded at 410 nm with ELISA reader. 
In each step 100 pL of solution was added and each sample 
was run in duplicate. The control wells were treated 
similarly but were devoid of antigen. 
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III RESULTS 
Antinuclear antibodies were detected in the sera 
of patients with SLE by Enzyme Linked Immunosorbent Assay 
(ELISA). The studies employed purified nuclei from goat 
liver as the source of antigen. A series of preliminary 
experiments with ANA positive sera were carried out to 
determine the effect of various parameters such as storage 
of nuclei below 0°C, concentration of nuclei, incubation 
period etc. 
1. Isolation of nuclei 
Goat liver was chosen as the source of nuclear 
antigens in view of easy availability in bulk besides 
being a rich source of these antigens. Nuclei were isola-
ted as described earlier (Ishaq and Ali, 1983b) and puri-
fied by centrifugation through a dense Ficoll gradient. 
The nuclei were stained using hematoxylin as a 
basic dye and observed under light microscope. The isola-
ted nuclei were 95 percent pure. 
ELISA of SLE serum on polystyrene plates coated 
with goat liver nuclie (Fig.1) indicated high titre of 
antinuclear antibodies. Normal human serum did not show 
appreciable binding. 
2. Antigen coating 
Adsorption of antigen was performed at room tempe-
rature for two hours and overnight at 4°C. The coating 
buffer was 0.05M carbonate-bicarbonate, pH 9.6. 
3. Storage of nuclei 
ELISA when carried out with nuclei as antigen 
that had been stored at -20°C upto one month showed almost 
no change in antigenicity (Fig.2). However, a considerable 
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Figure 1. Direct binding assay of antinuclear 
antibodies. SLE serum {—%-) and 
normal human serum (—TV—). 
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Figure 2. Direct binding assay for antinuclear 
antibody activity of isolated nuclei 
at different time intervals. 
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decrease in absorbance value was observed with the nuclei 
stored more than thirty days. It is therefore, suggested 
that isolated nuclei stored at -20°C can be used for 
ELISA for no longer than one month without appreciable 
loss in activity. 
4. Fixing of nuclei 
It was observed that the nuclei used as antigen 
does not settle but become adsorbed on the polystyrene 
surface. 
Polystyrene microtitre plate was incubated with 
various concentrations of antigen (100 to 2000 nuclei/ 
50pL) for two hours at room temperature and overnight 
at 4°C. The number of nuclei in the supernatant that 
remained unadsorbed were counted using hemacytometer. 
It was observed that the binding of nuclei to the poly-
styrene surface was 75-80% upto nuclie concentration 
of 2000/50pL. The plate was washed three times with ST-20 
and the number of unadsorbed nuclei in the supernatant 
was determined after each washing. The number of nuclei 
fixed on the polystyrene surface remain unaltered before 
and after washing. The plate was then incubated for 
4 hours at room temperature and the number of nuclei 
adsorbed on the surface determined again after each wash-
ing. The adsorption of nuclei on polystyrene surface 
was found to be unchanged (Fig.3). 
5. Concentration of nuclei 
ELISA was carried out with polystyrene microtitre 
plates coated with various concentrations of antigen 
(100-10,000 nuclei/SO^iL) with p-nitrophenyl phosphate 
(PNP-P) as substrate. The purpose was to find the optimal 
antigen concentration for coating. There was nearly linear 
relationship between binding and nuclei concentration 
upto 1000 nuclei/50pL after which a rapid decrease in 
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Figure 3. Adsorption profile of nuclei on 
microtitre plate. 
31 
activity with further increase in antigen concentration 
was noticed (Fig.4). ANA positive SLE serum was tested 
at three dilutions and in each case a similar profile 
was observed. The experiment was repeated a couple of 
times and the results were almost similar. 
6. ANA-ELISA 
Normal human sera and sera from patients with 
systemic lupus erythematosus were tested for antinuclear 
antibodies using p-nitrophenyl phosphate as enzyme subs-
trate. Normal human sera and sera from patients with 
non-rheumatic diseases were negative for antinuclear 
antibodies. 
Ten out of twelve (83%) SLE patients were positive 
for antibodies to ANA when purified nuclei were used 
as antigen (Fig. 5 and 6). ELISA was carried out with 
the same samples of SLE sera using nDNA as antigen. 
Table 2 shows the results obtained with various antibody 
positive SLE sera. 
The reference sera obtained from centre for disease 
control Atlanta, Georgia, USA with antibody specificity 
for nDNA, RNP, Sm, nucleolus, centromere, ANA (RNP, SSB/La, 
SSA/RO) and Scl-70 were analysed for antibody content 
against purified nuclei by ELISA. The RNP, Sm and nucleo-
lar reference sera demonstrated strong antibody activity 
(Fig.7 and 8). The reactivity obtained with reference 
sera specific for nDNA and Scl-70 is dipicted in Fig.9. 
The SSB/La and SSA/RO reference sera showed almost no 
binding with goat liver nuclei (Fig.8 and 9). The charac-
teristics of the reference sera as provided by the 
supplier and the titre obtained by ANA-ELISA are shown 
in Table 3. The end point titre for individual sera is 
expressed as the mean of duplicate samples. 
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Figure 4. Evaluation of critical concentration 
of nuclei for ANA-ELISA. 
Antibody positive SLE serum at 
a dilution of 1:1000 ( — # — ) , 1:2000 
( 0—) > and 1:4000 (—#—) . 
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Figure 5„ Direct binding assay of antinuclear 
antibodies. 
ANA positive SLE sera with different 
levels of antibody activity 
(___A ), (—6—) and normal 
human serum ( — O — ^ 
34 
E 
c 
o 
>4 
UJ 
o 
2 
< 
m 
Q: 
o 
(/) 
m 
< 
3-0 3-3 3-6 3-9 
-LOG SERUM DILUTION 
Figure 6. Direct binding assay of antinuclear 
antibodies. ANA positive sera (—9—), 
(__0-), (-A-), (-^y-), (—•—), and 
and normal human serum (—0—). 
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TABLE 2 
THE ANTIBODY BINDING ACTIVITY OF TWELVE SLE SERA 
AGAINST nDNA AND PURIFIED NUCLEI 
Sample Anti-nDNA Anti-ANA 
number activity activity 
1 . + + + + + + 
2. ++ + + 
3. + + + 
4. ++ ++ 
5. + + 
6. + + 
7. + + + 
8. + + + 
9. - + 
10. + 
11 . + + 
12. + ++ 
(+++) Highly Positive; (++) Moderately Positive; 
(+) Positive 
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Figure 7. Direct binding assay for the detection 
of antinuclear antibodies. 
( — • ) SLE serum, ( — # — ) anti-
RNP, (—D—) antinucleolar, (—4—) 
anticentromere and ( — O — ) Normal 
human serum, 
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Figure 8. Direct binding assay for detection 
of antinuclear antibodies. (—#—) 
SLE serum, (—•—) anti-Sm, ( A ) 
ANA (UIRNP/SSB-La/SSA-Ro), (—D—) 
anti SSA/RO and (—Q—^  Normal human 
serum• 
£)6 
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Figure 9. Direct binding assay for detection 
of antinuclear antibodies. ( —4J—) 
SLE serum, (—0—) anti-nDNA, (—4 ) 
anti-Scl-70, (—6 ) anti-SSB/La 
and (—Q—) normal human serum. 
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TABLE 3 
COMPARISON OF ANA REACTIVITY BY FANA AND ELISA 
ANA-Human 
reference 
serum 
1 . 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
no. 
Antibody 
activity 
against 
nDNA 
SSB/La 
Antinuclear 
antibody 
(U1RNP/SSB-La/ 
SSA/Ro) 
UlSnRNP 
Sm 
Antinuclear 
antibody 
nucleolar 
pattern 
SSA/Ro 
Antinuclear 
antibody 
(centromere 
pattern) 
Scl-70 
FANA Med 
titre 
1 :512 
ID/CIE-1 
1 :320 
ID-1:64 
ID-1:64 
1 :256 
ID-1 :16 
1 :640 
ID-1:4 
ian 
:40 
ANA-ELISA 
titre 
1 :3200 
No activity 
1 :1600 
>1 :3200 
>1 :3200 
1 :3200 
No activity 
1 :1600 
1 :3200 
ID = Immunodiffusion; CIE = Counterimmunoelectrophoresis 
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7. Precision 
Table 4 shows the intra- and interassay coefficient 
of variations for measurement of antinuclear antibodies 
in five positive SLE sera. A high degree of reproducibi-
lity of the assay procedure is evident from the data 
given. 
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TABLE 4 
REPRODUCIBILITY DATA FOR ANTINUCLEAR ANTIBODY ASSAY OF 
FOLLOWING SERA 
S.No. Sample _ _ Mean absorbance ± S.D. 
Intra-assay Inter-assay 
1. SLE 0.630±0.009 0.54+0.02 
(1.42) (3.70) 
2. SLE 0,45jf0,008 0.4U0.02 
(1.78) (4.87) 
3. SLE 0.390^0.008 0.4U0.03 
(2.05) (7.31) 
4. SLE 0.34^0.009 0.38+0.02 
(2.64) (5.26) 
5. SLE 0.38-1^ 0.003 0.43^0.05 
(0.78) (11.62) 
6. NHS 0.22+^0.002 0.1 8jf 0.02 
(0.909) (11.1) 
7. NHS 0.18-1^ 0.004 0.25^+0.02 
(2.22) (8.0) 
Tlie values in the parenthesis represent coefficient 
of variation 
Serum diluation 1:1000 
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IV DISCUSSION 
Autoantibodies to nuclear antigens have become 
important aids in the diagnosis of human autoimmune 
diseases (Tan, 1982). Some antibody specificities have 
been implicated in the pathogenesis of both human and 
murine SLE (Tan, 1982; Theofilopoulos, et al. 1985). 
The detection and quantitation of antinuclear antibodies 
rely on technology that has been in use over three 
decades. The fluorescent antinuclear antibody (FANA) 
test adopted from the technique of Coons and Kaplan 
(1950) has been widely used for detecting antinuclear 
antibodies in the sera of these patients. The substrates 
commonly used have usually been tissue sections or cell 
smears. FANA has the advantage of being easy to perform 
and a sensitive test system. Despite these advantages, 
FANA has been limited by certain short comings. For 
instance, not all laboratories are equipped to do fluore-
scence microscopy. Moreover, the standardization of 
the FANA has been difficult due to wide variations in 
reagent quality including fluorochrome conjugates, micro-
scopes with a variety of optic configurations and lack 
of a standard substrate that detects a wide variety 
of autoantibodies (Molden, et al. 1984; Beutner, 1974). 
The described method of ELISA represents a new 
approach for the detection of antibodies to nuclear 
autoimmune diseases. This technique allows the applica-
tion of nuclei isolated from goat liver as the source 
of antigen. Goat liver was chosen in view of its easy 
availability in bulk besides being rich source of nuclear 
antigens. 
Since the invention of ELISA technique, individual 
antinuclear antibodies are being detected and quantitated 
by ELISA. The solid phase being coated with purified 
antigen (Labrousse, et al., 1980; Halbert, et al., 1981; 
Pisetsky and Peters, 1981; Ali and Ali, 1983; Holliday, 
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et al. 1985). Almost all the known ANAs have been detected 
by ELISA (Maddison, et al. 1985; Geisler and Holer Madsen, 
1985; Ogata, et al. 1985; Costa and Monier, 1983; Kumar 
and All, 1984). 
Effect of various parameters was investigated 
on assay procedure. The critical concentration of nuclei 
for ANA-ELISA was evaluated by coating polystyrene plates 
with various concentrations of nuclei (100-10,000 nuclei/ 
50)iL) . A nearly linear relationship between antibody 
binding and nuclear concentration was obtained up to 
1000 nuclei/SOjjL after which a rapid decrease in activity 
with further increase in antigen concentration was noticed. 
The profiles obtained with three different dilutions 
of serum are typical of bell shaped curve generally obtai-
ned with quantitative precipitation titration. Although 
with the available data it is difficult to compare the 
two altogether different assay procedures. In view of 
sharp decline in activity after the absorption of 1000 
nuclei/well the experiment was repeated a couple of times 
and the results were almost similar each time. 
In the present study, sera of 12 patients with 
SLE were examined by ELISA using nDNA and purified nuclei 
as the source of antigens. Antibody binding against each 
of the two antigens was significant in 10 out of 12 '83%) 
sera. One patient had antinuclear antibodies against 
nuclei, but had no antibody activity against nDNA. This 
difference in reactivity could be due to the presence 
of antibodies in SLE sera against some nuclear antigen 
other than nDNA. Whereas, another patient although 
positive for antinuclear antibody activity, did not show 
reactivity with nDNA. The heterogeniety of SLE sera is 
well documented and the antibody activity with nDNA could 
be due to reactivity towards single stranded regions 
in nDNA which are practically impossible to remove to 
the extent of 100 percent. 
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In this study a serum dilution of 1:1000 was 
employed which when compared with nDNA binding at 1;100 
showed significantly increased activity in terms of titre 
and quantitative evaluation. 
Examination of various reference sera with known 
antibody specificities clearly demonstrates the sensiti-
vity of our technique. In this group of prototype sera, 
the ELISA was a more sensitive test, with RNP, Sm, nDNA, 
nucleolar, Scl-70, and ANA (U1RNP/SSB-La/SSA-Ro) sera 
demonstrating end point titre higher than the FANA assay. 
The mean end point titre of RNP and Sm obtained by ELISA 
was >1:3200. The end point titre obtained with nDNA, 
Scl-70 and nucleolar reference sera was six times higher 
than that of FANA. No antibody activity was obtained 
with SSA/RO and SSB/La antigen. The SSA/RO antigen has 
been described to be cytoplasmic in origin being complexed 
with several RNAs called Y1 and ¥5 RNAs (Tan, et al. 
1988). 
In summary, ELISA with nuclei bound to polystyrene 
surface is a reliable alternative to FANA in the detection 
of antinuclear antibodies. The method is simple, sensitive 
and utilizes small amount of serum (1:1000). Nuclei from 
liver besides being a rich source of antigen could detect 
a wide variety of antinuclear antibodies. 
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